Core Viewpoint - The company has received an expansion approval for its drug production license from the Jiangsu Provincial Drug Administration, allowing it to produce a recombinant shingles vaccine and related adjuvant components, enhancing its capabilities in the field of preventive biological products [1] Group 1: License Expansion Details - The company, Jiangsu Ruike Biotechnology Co., Ltd., has been granted an expansion of its drug production license with the number Su20210057 [1] - The license is effective from November 5, 2025, and will remain valid until November 14, 2026 [1] - The new production addresses include facilities for the recombinant shingles vaccine (CHO cells) and adjuvant components, with specific production lines for both the vaccine and the adjuvant [1] Group 2: Production Facilities - The new production site for the recombinant shingles vaccine includes a production line for CHO cell raw liquid and an adjuvant production line [1] - Additional facilities include a warehouse and laboratory functions at a new address in Taizhou, Jiangsu Province [1] - The adjuvant component, monophosphoryl lipid A (MPL), will also have dedicated production lines at the specified locations [1]
瑞科生物-B(02179.HK)取得重组带状疱疹疫苗《药品生产许可证》增项